Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.1.180NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.464NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.234NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.231NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.243NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-22381.5US
B.1.517NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.291NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.258NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.349NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.314NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.132NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.38NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.42NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.62NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GA.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.23NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.3.13NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.160NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JV.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XCYNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HK.16NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EK.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HV.1.10NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HV.1.6.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EF.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BU.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.1.38NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.34NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.7.12NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-25520.9US
CJ.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.21NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.4.6.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CM.7.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.3.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.22NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.7.19NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FA.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EE.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.72NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBJ.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.14NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CK.2.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.397NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.277NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.294NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.81NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HV.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.2.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used